TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Report injection drug use in the 6 months before screening~* Possess a Thai National Identification Card~* Laboratory values as follows within 2 weeks before enrollment:~* HIV oral fluid test non-reactive at screening and pre-enrollment visits~* Hemoglobin 9 gm/dL~* ALT and AST 2.5 x upper limit of normal (ULN)~* Total bilirubin 1.5 mg/dL~* Serum amylase 1.5 x ULN~* Serum phosphorus 2.2 mg/dL~* No evidence of current or chronic Hepatitis B infection by serology~* Calculated creatinine clearance 60 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min = Male: (140 - age in years) x (wt in kg)/72 x (serum creatinine in mg/dL) Female:(140 - age in years) x (wt in kg) x 0.85/72 x (serum creatinine in mg/dL)~* Willing to abstain from sexual intercourse or use effective contraception during the trial (oral, injection, or barrier), for women~* Willing and able to provide informed consent for study participation~* Available and committed to DOT or monthly follow-up for at least 12 months~Exclusion Criteria:~* Clinic physicians will determine if a subject with chronic illness requiring prescription medication can not enroll (medication used for drug treatment is allowed)~* Positive urine pregnancy test~* Breastfeeding~* History of significant renal, liver, or bone disease~* Any other clinical condition or prior therapy that, in the opinion of the clinic physician, would make the subject unsuitable for the study or unable to comply with the dosing requirements~* Concurrent participation in any other HIV prevention trial or drug/vaccine safety trial. AIDSVAX B/E HIV vaccine trial (CDC protocol #2076) participants and Extension Study (CDC protocol #3750) participants may be screened for enrollment in the Bangkok Tenofovir Study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- tenofovir disoproxil fumarate (Type: EXPERIMENTAL): Participants in the Tenofovir arm will receive daily oral tenofovir
- Placebo (Type: PLACEBO_COMPARATOR): Participants in the Placebo are will receive daily oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female travellers ≥ 18 years of age.~  * General good health.~ * Written informed consent.~ * Ability to attend all visits scheduled in this study.~ * Travellers who have previously got a primary vaccination series of 2 or 3 doses of JE-MB and now receive a booster vaccination , either MB-JEV or IXIARO, at the travel clinic for their journey to Asia, OR~ * Travellers with no previous vaccination against JE who are given the primary vaccination series with IXIARO at a travel clinic prior to their journey to Asia.~Exclusion Criteria:~* - \< 18 years of age.~* Acute disease at the time of enrollment.~* Pregnancy or lactation.~* Known immunodeficiency or immune suppressive treatment.~* Any chronic illness that might interfere with the immune response; history of JE.~* Alcohol or drug abuse.~* Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A) primary immunization with MB-JEV (Type: ACTIVE_COMPARATOR): Volunteers immunized with MB-JEV
- Primary and booster MBJEV vaccinations (Type: ACTIVE_COMPARATOR): Booster immunization with MB-JEV of vaccinees primed with MB-JEV
- C) primary immunizations with Ixiaro (Type: ACTIVE_COMPARATOR): Primary immunization with Ixiaro 2 dose
- S) Ixiaro booster to MBJEV primed (Type: ACTIVE_COMPARATOR): Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes~2. HbA1c ≥ 7.5%~3. Age ≥ 30~4. low HDL-C (\<40 mg/dl in men or \<50 mg/dl in women) and having 1 or more risk factors: 1) Body mass index (BMI) ≥ 25 kg/m2 (overweight); 2) LDL-C level ≥ 130 mg/dl; 3) TG level ≥150 mg/dl; 4) Systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥140/90 mmHg or taking antihypertensive medication; 5) Current smoker; 6) Family history of CHD.~Exclusion Criteria:~1. Contraindication to rosuvastatin~2. Pregnant or breast feeding women~3. Reproductive-age women who refuse contraception~4. Type 1 diabetes, gestational diabetes, or diabetes with secondary cause~5. Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)~6. Renal failure (Cr \> 2.0)~7. Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment)~8. Not appropriate for lipid lowering treatment~9. Medications which affect glycemic control~10. Diseases which affect efficacy and safety of statin~11. Other clinical trial within 30 days

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Venous Thrombo Embolism (VTE).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Inclusion_Criteria~* Acute symptomatic deep vein thrombosis (DVT)~* Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by objective testing~Exclusion criteria:~Exclusion_Criteria~* Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE.~* Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) \> 2x ULN~* Severe renal impairment (estimated creatinine clearance \<= 30 ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
- Warfarin (INR of 2.0-3.0) (Type: ACTIVE_COMPARATOR): Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 37 weeks gestation~* Exposure to opiates in utero~* Demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment~Exclusion Criteria:~* Major congenital malformations and/or intrauterine growth retardation~* Medical illness requiring intensification of medical therapy. This includes, but is not limited to suspected sepsis requiring antibiotic therapy.~* Hypoglycemia requiring treatment with intravenous dextrose.~* Bilirubin \>20 mg/dL (The need for phototherapy is not exclusionary)~* Concomitant benzodiazepine or severe alcohol abuse , self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother 30 days prior to birth,~* Concomitant use of Cytrochrom (CYP) 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment~* Seizure activity or other neurologic abnormality~* Breast feeding~* Inability of mother to give informed consent due to co-morbid psychiatric diagnosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sublingual buprenorphine (Type: EXPERIMENTAL): This is the group that received active sublingual buprenorphine and placebo for oral morphine
- oral morphine (Type: ACTIVE_COMPARATOR): This is the group that received active oral morphine and placebo for sublingual buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A healthy male or female, 19 to 64 years of age (not having reached the 65th birthday) at the time of study vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding administration of study vaccine, or planned use during the active phase of the study.~* Chronic administration of immunosuppressants or within six months prior to administration of study vaccine.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of administration of study vaccine (with the exception of an influenza vaccine).~* Administration of a diphtheria-tetanus (Td) booster within previous five years.~* Administration of Tdap vaccine at any time prior to study entry. History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or any component of the study vaccines.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Boostrix Group (Type: EXPERIMENTAL): Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
- Adacel Group (Type: EXPERIMENTAL): Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, 19 years ≤ age ≥ 80 years~2. Those who be expected to do operation about non palpable breast lesion excision~3. Those who have lesion vial mammography and breast ultrasound~4. Written consent voluntarily to participate in this clinical trial~Exclusion Criteria:~1. Patients who be expected to do mastectomy~2. Patients with multiple tumor or diffuse microcalcification~3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times local resection~4. Patients who were treated with moderate to severe radiotherapy~5. Patients who were treated with neoadjuvant Chemotherapy~6. Patients with active invading skin connective tissue disease~7. Patients with local progressing breast cancer or inflammatory local progressing breast cancer~8. Patients who have an allergy to investigational product or any of the component with the Investigational product~9. Patients who disagree about contraception for this clinical trial~10. A pregnant women or lactating women~11. Patients who participated in other clinical trials within the past 12 weeks from the date of informed consent~12. Patients who investigators determines unsuitable for this clinical trial

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LuminoMark inj. 0.1mL (Type: EXPERIMENTAL): Injection LuminoMark inj. 0.1mL once in this study.
- LuminoMark inj. 0.2mL (Type: EXPERIMENTAL): Injection LuminoMark inj. 0.2mL once in this study.
- Charcotrace Inj. (Type: ACTIVE_COMPARATOR): Charcotrace Inj. about 0.3\~1mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* BMI between 18.0 and 40.0 kg/m2 inclusive~* Male or female subjects between 18 and 75 years of age~* Stable dosage of medication for 30 days~* for dialysis patients, receiving chronic and stable maintenance hemodialysis for at least 3 months~Exclusion Criteria:~* Functioning transplanted solid organ~* High tyramine diet~* Significant, unstable, or life-threatening condition or organ or system condition or disease, other than kidney disease in renal subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Renal Impairment Nondialyzed (Type: EXPERIMENTAL): None
- Renal Impairment Dialyzed (Type: EXPERIMENTAL): None
- Matched Control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>=40 years of age, diagnosed COPD with symptoms \>=2 years, pre-bronchodilatory FEV1 \<=50% of PN~Exclusion Criteria:~* Current respiratory tract disorder other than COPD, history of asthma or rhinitis, significant or unstable cardiovascular disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symbicort+TIO (Type: ACTIVE_COMPARATOR): Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
- Spiriva® + Placebo Turbuhaler (Type: ACTIVE_COMPARATOR): Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has completed the 6-Month Treatment Period of their respective Pivotal Study (either Study M12-815 or Study M12-817).~* Participant did not meet removal criteria in bone mineral density (BMD) decrease in the spine, total hip and femoral neck at Month 6 of the Treatment Period of their respective Pivotal Study~* Participant has negative urine and/or serum pregnancy test(s) results were consistently negative during the Treatment Period of their respective Pivotal Study and prior to first dose in this study.~* Participant's endometrial biopsy from the Month 6 Visit of their respective Pivotal Study shows no clinically significant endometrial pathology.~Exclusion Criteria:~* Participant met criteria for removal from therapy in her respective Pivotal Study.~* Participant is planning a pregnancy within the next 18 months.~* Participant has current suicidal markers as noted at the Month 6 visit of her respective pivotal study.~* Participant has any new medical conditions that may be unsuitable for participation.~* Participant is using any systemic corticosteroids for over 14 days or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA) (Type: EXPERIMENTAL): Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
- Elagolix (Type: EXPERIMENTAL): Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participated in study 580299/001 and received all three doses of vaccine/placebo.~* Written informed consent obtained from the subject prior to enrollment~Exclusion Criteria:~* Decoding of the subject's treatment allocation to either the subject or the investigator in study 580299/001.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with early or advanced idiopathic Parkinson's Disease~* Patients with advanced idiopathic Parkinson's Disease: intake of Levodopa on a stable dose of at least 200 mg/day~* Unsatisfactory control of Parkinson's Disease motor symptoms under current treatment~* Patients experiencing Apathy associated with Parkinson's Disease~* Hoehn and Yahr stage score of I to IV~* Mini-Mental State Examination score ≥ 25~* If an antidepressant drug is taken, the dose must be stable~Exclusion Criteria:~* Therapy with a Dopamine agonist~* Discontinuation from pervious therapy with a dopamine agonist after an adequate length of treatment, at adequate dose, due to lack of efficacy~* Any medical or psychiatric condition that jeopardizes / compromises patient's ability for participation~* Patient has received Neuroleptics, Dopamine releasing substances, Dopamine modulating substances, Alpha-Methyldopa, Metoclopramide, MAO-A inhibitors, Budipine, or Tolcapone~* Electroconvulsive therapy~* Patient has a~  * current/anticipated psychotherapy or behavior therapy~ * history of deep brain stimulation~ * history of suicide attempt or has suicidal ideation~ * impulse control disorder~ * severe Depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine, high dose (Type: EXPERIMENTAL): Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
- Rotigotine, low dose (Type: EXPERIMENTAL): Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
- Placebo (Type: PLACEBO_COMPARATOR): Placebo transdermal patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete